Screening for primary aldosteronism in patients newly diagnosed with hypertension would maximise treatment benefits and minimise end-organ damage
Hypertension is the second leading risk factor for death and disability globally.1 In Australia, 6 million adults are affected2 and, on the basis of the evidence we discuss in this article, a significant proportion may have primary aldosteronism (PA) as a secondary cause of their hypertension. PA, of which a subset has been known as Conn syndrome, is a disease characterised by excessive autonomous aldosterone production.3 Contrary to the traditional teaching that this is both rare and benign, PA is common, specifically treatable, and associated with significant cardiovascular morbidity and mortality.4-6
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.